- $44.47m
- $54.27m
- $44.05m
Brief: Sanuwave Announces Plans To Attend 7 Medical And Investor Conferences Totally In March, April & May
Brief: Sanuwave Receives FDA De Novo Decision To Immediately Market Dermapace System For Treatment Of Diabetic Foot Ulcers In U.S.
Brief: Sanuwave signs definitive agreement with Mundimed for Brazil JV with an expected NPV of over $25 million
Brief: Sanuwave Health Q2 revenue fell 45 percent to $111,000
Brief: Sanuwave Health announces data from dermapace study for treatment of diabetic foot ulcers
Brief: SANUWAVE Health provides an update on the dermapace clinical trial
Brief: SANUWAVE Health Q1 loss per share $0.02